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InﬂuenzaVaccination throughmucosal surfaces has been shown to elicit antiviral immune responses against a number of
mucosal pathogens. Here we demonstrate that both mucosal and systemic immune responses can be elicited
against a model HIV-1 CN54gp140 antigen when cation-complexed plasmid DNA vaccines are applied topically
to the murine pulmonary mucosa as an immune priming strategy. Furthermore, using an inﬂuenza challenge
model we show that a plasmid DNA vaccine complexed to a less toxic form of PEI called dPEI (a nearly fully
hydrolysed linear PEI with 11% additional free protonatable nitrogen atoms) can provide signiﬁcant protection
against a respiratory challenge infection in mice. Furthermore, we show that dPEI polyplexes have the potential
to transfect not only mucosal epithelium, but also to enter deeper into tissues through the modulation of tight
junction integrity. Taken together, these results demonstrate that less toxic forms of PEI can be effective delivery
vehicles for plasmid DNAs to elicit cellular and humoral protective responses in vivo. Moreover, our observations
suggest that these less toxic derivatives of PEI could be utilised for topical plasmid DNA vaccine delivery to
human mucosal tissue surfaces, and that this application may permit dissemination of the immune responses
through the linked mucosal network thus providing protective immunity at distal portals of pathogen entry.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The use of non-viral gene delivery systems has signiﬁcant advan-
tages for the treatment aswell as prevention of awide range of clinically
relevant diseases. A number of delivery systems have been successfully
employed in vitro and in vivo for the delivery of biologically relevant
protein-encoding plasmids including cationic compounds based on
polymers such as polyethylenimine (PEI) [1,2] or polylysine [3] and
newer branched and hyperbranched derivatives of these linear mole-
cules. Numerous lipid based emulsions have also been employed such
as liposomes [4] and DOTAP/Squalene [5,6] formulations. All these cat-
ionic compounds are used for their intrinsic electrochemical property of
interacting with and condensing the negatively charged DNA. These in-
teractions allow the formation of complexes commonly referred to as
polyplexes and lipoplexes depending on whether they are derived
from polymer or lipid interactions. Due to its transfection efﬁciency
and relatively low cost, PEI based gene delivery has become commonity Group, Section of Infectious
don W2 1PG, UK. Tel.: +44 20
.
.V. Open access under CC BY-NC-ND liplace with numerous publications reporting on its merits. However
the application of PEI as an in vivogene delivery tool has beenhampered
by its apparent toxicity [7,8], deemed as a signiﬁcant obstacle for
mucosally applied vaccine applications, particularly when nasal or pul-
monary delivery is required. Therefore the pursuit of DNA complexing
agents with low toxicity and high transfection abilities is a primary
goal for the DNA delivery ﬁeld.
As a wide range of pathogens utilise mucosal surfaces as portals of
entry into the body, the successful establishment of effective mucosal
immunity has the potential to provide signiﬁcant protection to these
at risk surfaces from pathogen invasion. Mucosal delivery of vaccines
can stimulate bothmucosal and systemic immune responseswhile con-
ventional systemic vaccinations are generally poor at activating muco-
sal responses [9]. Furthermore, the provision of protective responses
at pathogen portals of entry, has the potential to either prevent infec-
tions altogether, eliminate the infection at the earliest time points, or
at the very least, contain infections and reduce spread and the burden
of infection.
Here we evaluated two different cationic compounds, Dope/Dotap/
Squalene (DDS) and deacylated PEI (dPEI), for their capacity to con-
dense plasmid DNA encoding amodel trimeric gp140 vaccine candidate
as a mucosal priming strategy. dPEI and DDS were chosen as mucosal
transfection reagents as 1) dPEI is a nearly fully hydrolysed linear PEI
with 11% additional free protonatable nitrogen atoms, enabling more
efﬁcient compacting of DNA, reduced toxicity and higher transfectioncense.
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and has been reported to be 200 times better at transfecting than com-
mercial liposome carriers [5]. Previous studies conducted within our
laboratory have shown the mucosal delivery of unadjuvanted gp140
protein to be ineffective at generating speciﬁc immune responses
[11,12]. Thus we investigated the use of DNA-cationic complexes as a
mucosal priming strategy, capable of being boosted by homologous
protein. In this report we show that a DNA vaccine delivered topically
to mucosal surfaces can prime immune responses. In addition, we
show that the DDS- and dPEI-complexed DNA vaccine formulations
were capable of generating strong systemic and mucosal humoral re-
sponses as well as activating cellular responses. Finally, we show that
dPEI is superior to DDS in the magnitude of elicited immune responses
and that dPEI-DNA conveyed a higher degree of protection in a chal-
lenge model. Taken together, this study demonstrates the potential of
dPEI as a topical mucosal delivery strategy.
2. Materials and methods
2.1. Plasmids and reagents
The HIV-1 CN54gp140 clade C Env glycoprotein expressing plas-
mid (gp140) was a kind gift from Roger Tatoud. The Inﬂuenza A
virus (A/Aichi/2/1968(H3N2)) haemagglutinin (X31-HA) gene (GenBank
accession no. CY121117.1) was synthesised and codon optomised for
maximal expression in mice using the OptimumGene™ algorithm
(GenScript,). The HA gene insert was subsequently cloned into the
pmaxFP™-Red C vector (Lonza, UK). Large scale plasmid production
was carried out using an Endo free Gigaprep kit (Qiagen, UK). Cationic
dPEI (PEI Max MW 40,000 kDa), branched PEI (bPEI) and DDS emul-
sions were from Polysciences (Ger), Sigma Aldrich (UK) and Particle
Sciences (U.S.A.) respectively. Homologous recombinant CN54-gp140
protein was purchased from Polymun (Austria) and the H3N2 A/Aichi/
2/1968 was purchased from Sino Biological Inc., (China).
2.2. Plasmid cation complex formation
Cationic dPEI and bPEI were dissolved in sterile distilled DNAse free
water to a ﬁnal concentration of 5 mg/ml and 20 mg/mlwhile DDSwas
provided as a 24 mg/ml emulsion. Complex formation was achieved by
the addition of pre-diluted cation in sterile distilledwater to pre-diluted
anionic DNA in sterile distilled water. For dPEI, bPEI and DDS, either
2 μg, 0.5 μg or 0.39 μl cation/0.5 μg plasmid DNA was used to generate
dPEI-DNA, bPEI-DNA or DDS-DNA formulations. Resulting transfection
particles were immediately vortexed at low speed for 15 s before rest-
ing for 15 min at room temperature.
2.3. Assessment of cell toxicity associated with various cationic compounds
Caco-2 cells were seeded in a 96 well ﬂat bottomed tissue culture
plate using complete RPMI (20% FCS). When the cells reached 70%
conﬂuency, the media was removed and replaced with 200 μl incom-
plete DMEM for 1 h. The cells were washed and DDS-DNA, dPEI-DNA,
and N9were added to the cells in a ﬁnal volume of 200 μl of incomplete
RPMI before 4 hour incubation at 37 °C. The cells were again washed
and incubatedwithmedia containingMTT (200 μl; 0.5 mg/ml). Follow-
ing incubation for 2 h at 37 °C, the media were removed and the cells
were lysed using lysis buffer (98% isopropanol/2% 2 N HCL). Well con-
tents were aspirated and adsorbance was determined using a spectro-
photometer at 570 nm.
2.4. Determination of DNA-cation size using NanoSight
DNA-cation complex formation was analysed bymeasuring the rate
of Brownian motion using a NanoSight LM10-HS system (NanoSight,
Amesbury, UK) equipped with video capture and particle trackingsoftware. Vaccine samples were prepared and pre-diluted in water ac-
cordingly. The samples were then injected into the viewing chamber
and visualised using a focused laser (405 nm, 65 mW) and a Scientiﬁc
CMOS Image Sensor. Particles were recorded at room temperature for
60 s, withmanual shutter and gain adjustments. Samples were analysed
using the NTA2.3 software.
2.5. DNA transwell studies using Caco-2 monolayers and CHO acceptor
cells
The human adenocarcinoma cell line, Caco-2 and Chinese hamster
ovary, CHO, cells were used asmodel epithelia with intact tight junction
integrity and easy to transfect acceptor cells in a transwell transfection
assay (see Supplementary materials for full details).
2.6. Immunisation, sampling and infections
Female BALB/c mice (Harlan, UK), 6–8 weeks old, were placed
into groups of n = 6 and housed in a fully acclimatised room. All an-
imals were handled and procedures performed in accordance with
the terms of a project licence granted under the UK Home Ofﬁce An-
imals (Scientiﬁc Procedures) Act 1986. Food and water were supplied
ad libitum. Lightly anesthestised mice were placed in the supine posi-
tion with all vaccinations administered as nasal drops, with delivery
evenly distributed to each nare. Speciﬁcally, mice recieved3 DNA
primes every 2 weeks with 20 μg/50 μl CN54-gp140 DNA-cation for-
mulation followed by 3 protein boosts every 2 weeks with 20 μg/20 μl
CN54-gp140. For inﬂuenza studies, empty vector (pmaxFP™-Red C)
or pmax-X31 was used to prime followed by recombinant HA boost.
A full description of sampling and infection protocols is given in the
Supplementary material.
2.7. Immunohistochemistry
Penile tissue frompatients undergoing gender reassignment surgery
(local Research Ethics Committee approval was obtained) was used to
assess polyplex transfection of model human mucosal tissues. Human
penile glans tissuewas cut into 3 mmby 3 mmexplantswhile carefully
removing asmuch stromal tissue as possible. The explantswerewashed
then incubated in incomplete RPMI for 1 h within a 48 well tissue cul-
ture plate. The explants were then used in transfection experiments. A
full description of experimental protocols used is shown in the Supple-
mentary methods.
2.8. Antigen-speciﬁc immunoglobulin ELISA
We followed an in-house developed ELISA protocol to measure
antigen-speciﬁc Immunoglobulin concentrations in serum and muco-
sal lavage. Full details of methods used are included in the Supple-
mentary methods section.
2.9. Tissue processing for ELISpot and ﬂow cytometry
Lymphocyte cultures were derived from single cell suspensions
from spleens of immunised and control mice. Brieﬂy, mice were
euthanised, and their spleens were removed aseptically and placed
into individual 20 ml universal tubes (Greiner, UK) containing 2 ml
RPMI 1640 medium (Sigma Aldrich Ltd, UK). The spleens were then
placed into Petri dishes and single cell suspensions made by disrupting
the spleens. This was achieved by grinding the spleens through a 70 μm
Nylon Cell Strainers (BD Falcon, UK) using forceps. The cell suspensions
were then centrifuged at 350 g for 10 min. The supernatants were
decanted and the pelleted cells re-suspended in ACK lysis buffer for
5 min (Gibco, UK). The cell suspensions were vortexed and centrifuged
at 350 g for 10 min. The pelleted cells were decanted and re-suspended
in 1 ml RPMI 1640 medium. This step was repeated three times with
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100 μm Filcon unit (BD Biosciences, UK). The cells were counted using
a hemocytometer.2.10. Antigen-speciﬁc ELISpot
Antigen-speciﬁc IgG and IgA spleen ELISpot assays (MABTECH, UK)
were carried out as per the manufacturer's instructions. A full descrip-
tion of the experimental protocol is provided in the Supplementary
methods.2.11. Flow cytometric assessment of T cell responses in splenocytes
Isolated single cell cultures of murine splenocytes were assessed for
reactivity against two pools each containing 78 peptides of 15-mers
overlapping by 11 aa of HIV-1 CN54gp140 Env (Insight Biotechnology,
UK) using a FACS Canto II instrument with FACS Diva software. Data
analysiswas performedwith FlowJo (Treestar Inc., OR, USA). Full details
are provided in the Supplementary methods section.2.12. Statistical analysis
Statistical analysis of the data was carried out using aMann–Whitney,
U-test using GraphPad PRISM software.Fig. 1. DDS and dPEI are less toxic transfection reagents than bPEI and N9 and condense
DNA into nanometer-sized particles. The human adenocarcinoma cell line Caco-2 was
cultured to 75% conﬂuency before the addition of DNA-cation formulations. The com-
plexes were incubated with the cells for 4 h before cell viability was tested using an
MTT dye reduction assay (A). Polyplex and lipoplex formations were veriﬁed using a
NanoSight LM10-HS system. Images represent results from nanoparticle tracking anal-
ysis (NTA) video capture (B). The particle size (x-axis) versus relative intensity (y-axis)
of vaccine formulations generated by complexing DNA and cations (C). Normalised
particle volume nm3 × 1012/ml versus particle size for DDS (red line) versus
DDS-DNA (black line) (D) and dPEI (red line) versus dPEI-DNA (black line) (E).3. Results
3.1. DDS-DNA and dPEI-DNA complexes were less toxic than bPEI-DNA
and condensed DNA to form nanometer-sized transfection particles
Transfection particles were assessed for toxicity using a standard
MTT assay and the epithelial cell line Caco-2. DDS-DNA transfection
particles displayed no detectable toxicity as determined by MTT assay
and its associated dimethylthiazol-2-yl-2,5-diphenyltetrazolium bro-
mide reduction to formazan (Fig. 1a). The bPEI-DNA and surfactant
Nonoxynol-9 (N9), positive controls both showed high levels of tox-
icity with cell viabilities of only 16.4% and 17% respectively, while
dPEI-DNA exhibited moderate levels of cell toxicity with Caco-2
cell viability being reduced to 45.8% (±7%). Similar results were
seen with the Calu-3 respiratory cell line (data not shown). Due to
the high levels of toxicity of the bPEI-DNA, it was omitted from fur-
ther evaluation.
Polyplex and lipoplex formations were visually veriﬁed using a
NanoSight LM10-HS system (Fig. 1b). The Images are taken from
the video capture of the Nanosight tracking analysis. Successful parti-
cle formation was observed for the dPEI-DNA polyplex formulation
while no observable difference could be visually assessed for the
DDS-DNA lipoplex formulations due to the pre-existing particulate
nature of DDS (Fig. 1b). The size of resulting DNA-cation transfection
particles was assessed using the nanoparticle tracking analysis (NTA),
after the incubation of the cationic compounds with 20 μg DNA. Here
we formulated 80 μg dPEI, or 15.6 μl DDS with 20 μg (9.52 μl) DNA in
a ﬁnal 50 μl volume made up in dH20. Complexing DNA with dPEI
resulted in 14.96 × 108 particles/ml in the vaccine formulation with
a mean diameter of 163 nm, while the complexing of DNA with DDS
resulted in a vaccine formulation consisting of 6.8 × 109 particles/ml
with a larger mean diameter of 206 nm (Fig. 1c). Interestingly, the ad-
dition of DNA to cation solutions resulted in a change in particle size.
The addition of DNA to DDS resulted in a reduction in particle size and
an increase in relative intensity of the smaller particles (Fig. 1d), while
the addition of DNA to dPEI resulted in an increase in the detected par-
ticle size (Fig. 1e).3.2. DDS-DNA and dPEI-DNA elicited antigen-speciﬁc IgG in serum and
established a population of systemic antigen-speciﬁc IgG+ and IgA+ B
cells
Due to toxicity issues, in vivo assessmentwas carried out on only the
DDS-DNA and the dPEI-DNA cationic formulations. All immunisations
were pulmonary applications of the complexes or recombinant protein.
Antigen-speciﬁc immune responses were assessed before and after
each CN54gp140 protein boost. We found that immediately after the
ﬁnal cation-DNA immunisation and 1st protein boost, DDS-DNA and
dPEI-DNA transfection particles generated detectable humoral antibody
responses in serum. The vaccine antigen-speciﬁc serum IgG responses
elicited to the DDS-DNA and dPEI-DNA peaked after the third boost
with 480 and 632 μg/ml of speciﬁc antibodybeing detected in serum re-
spectively (Fig. 2a). No serum IgG responses were detected for the nasal
gp140 protein alone vaccine regimen. Evaluation of splenocyte cultures
by antigen-speciﬁc IgG ELISpot corroborated the ELISA data and
Fig. 2. DNA prime-protein boost vaccination regimens result in antigen-speciﬁc humoral
responses. FemaleBALB/cmice (n = 6per group)were vaccinated 3 times at 2 week inter-
vals with DNA followed by three protein boost vaccinations at 2 week intervals. Antigen-
speciﬁc IgG antibody responses were recorded oneweek after each protein-boost vaccina-
tion until the end of the study, week 10 (A). Antibody results are expressed as geometric
means of the group (μg/ml + SEM). Antibody secreting IgG (B) and IgA (C) cells were
determined at the end of the experiment (week 10), using a commercially available direct
ELISPOT assay as per the manufacturer's instructions. Results represent group means
of Spot Forming Units (SFU)/million antigen stimulated cells (+SEM). Statistical sig-
niﬁcance was assessed against the gp140 protein control group using Mann Whitney
U test with *p ≤ 0.05 or **p ≤ 0.005.
Fig. 3. Vaccine-induced T cell responses are generated after DNA prime-protein boost
regimens. Vaccinated mice were sacriﬁced one week after the ﬁnal protein boost vac-
cination and their splenocytes assessed for antigen-reactive T cells using 2 sets of
15mer overlapping by 11 amino acid peptide pools. Flow cytometric analysis of antigen-
speciﬁc T cells was achieved by a progressive gating strategy to identify CD3+CD4+ or
CD3+CD8+ T cell populations. Mean percentages of the peptide pool-reactive CD4+ (A)
and CD8+ (B) T cellswithin vaccination groups (after exposure to stimulation) expressing
IFN-γ, IL-2 and TNF-α. Statistical signiﬁcance was assessed using Mann Whitney U test
with *p ≤ 0.05 or **p ≤ 0.005.
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(SFU) of 4 (±1.6), 154.3 (±57.9), and 196.4 (±43.4) were detected for
gp140, DDS-DNA, and dPEI-DNA treatment groups respectively
(Fig. 2b). Similar responses were seen for IgA+ B cells in splenocyte
cultures where 44 (±9.6), 141.3 (±47.8), and 137 (±32.3) SFU were
detected for the gp140, DDS-DNA and dPEI-DNA treatment groups re-
spectively (Fig. 2c). Furthermore, 100% of animals in the dPEI-DNA
treatment regimen had antigen-speciﬁc IgG+ and IgA+ B cells in
splenocyte cultures while only 66.6% of animals in the DDS-DNA treat-
ment regimen had IgG+ and IgA+ SFU above background levels.
3.3. DDS-DNA and dPEI-DNA transfection complexes generated
antigen-speciﬁc IFN-γ, IL-2 and TNF-α producing CD4+ T cells
To characterise vaccine induced T cell responses in immunised an-
imals, we performed intracellular cytokine staining (ICS) on isolated
splenocytes using two peptide pools (15-mers overlapping by 11)covering the entire CN54gp140 Env sequence, and evaluated IFN-γ,
IL-2 and TNF-α production. Splenocytes were harvested after the
third CN54gp140 protein boost and the phenotype and functional re-
sponse was assessed after the six hour stimulation in the presence of
the pooled peptides and brefeldin A using standard ICS protocols with
multi-parameter ﬂow-cytometric analysis. With a sequential gating
strategy, we removed doublets and gated on either CD4+ or CD8+ T
lymphocytes. We found that CD4+ T cells in all vaccination groups
produced IFN-γ, TNF-α and IL-2 in response to stimulation with the
peptide pools, with the cation-DNA primed animals having a higher
percentage of vaccine-antigen responsive cells than the gp140 pro-
tein alone group. The animals that had received dPEI-DNA polyplexes
exhibited less variable responses than the DDS-DNA treated animals
enabling the detection of signiﬁcant differences from the CN54gp140
treated animals (Fig. 3a). Analysis of the CD8+ T cell response revealed
that responseswere almost exclusively directed toward peptides within
Fig. 4. DDS- and dPEI-DNA induce antigen-speciﬁc antibody responses in the vaginal
mucosa. Antigen-speciﬁc IgG (A) and IgA (B) from mucosal lavage were assessed
(n = 6) after the ﬁnal protein boost. Antibody results are expressed as group means
(ng/ml + SEM). Statistical signiﬁcance was assessed using Mann Whitney U test with
*p ≤ 0.05 or **p ≤ 0.005.
Fig. 5. DDS- and dPEI-DNA complexes can protect against inﬂuenza infection challenge.
Antigen-speciﬁc IgG antibody responses (n = 6 per group) were recorded one week
after 3 cation-complexed DNA prime vaccinations (20 μg/50 μl volume) and a single re-
combinant HA protein boost vaccination (10 μg/50 μl). Antibody results are expressed
as geometric means of the group (ng/ml + SEM) (A). Mean IFN-γ T cell responses from
splenocyte cultures stimulated with whole antigen HA were assessed on day 4
post-inﬂuenza infection using a commercially available ELISPOT assay. Results represent
the means of (n = 6) SFU/million splenocytes (B). Mice were infected with 5 HA units
of Inﬂuenza X-31. Antigen-speciﬁc IgG (C) and IgA (D) fromnasal lavagewere performed.
Bodyweights for the different vaccination groups are expressed as a percentage relative to
day 0 (E). Inﬂuenza viral loads in lung samples were assessed and expressed as plaque
forming units (PFU/ml) (F). Statistical signiﬁcance was assessed using Mann Whitney U
test with *p ≤ 0.05 or **p ≤ 0.005.
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(Fig. 3b). Furthermore, only low-level CD8+ T cell responses were
detected in the DDS-DNA vaccine groups with only IFN-γ responses
reaching signiﬁcance (*p = 0.0135) compared to the gp140 control
group. However, the dPEI-DNAprimeboost vaccination regimen elicited
higher CD8+ responseswith signiﬁcantly higher IFN-γ (**p = 0.008) and
IL-2 (**p = 0.008) positive cells being generated than the CN54gp140
control group. The percentages of TNF-α positive CD8+ cells observed
in each group were not signiﬁcantly different (Fig. 3b). To support and
conﬁrm the ICS staining, an IFN-γ and IL-2T cell ELISpot assay was used
(Suppl Fig. 1). Using the ELISpot assay both the DDS-DNA (**p =
0.0022) and dPEI-DNA (**p = 0.0043) formulations generated signiﬁ-
cant numbers of IFN-γ SFU/106 splenocytes with mean values of 332.3
(±280) and 444.4 (±217) respectively. For IL-2 producing lymphocytes,
again the DDS-DNA (*p = 0.037) and dPEI-DNA (*p = 0.022) formula-
tions elicited signiﬁcantly higher SFU/106 than the CN54gp140 protein
treated animals with average IL-2 SFU values of 114 (±84.9) and 142.8
(±94.7) (Suppl. Fig. 1). Only the dPEI-DNA prime-CN54gp140 protein
boost regimen generated signiﬁcant numbers of TNF-α positive cells(Fig. 3a). TNF-α production was not assessed by ELISpot due to the lack
of a commercially available ELISpot kit.
3.4. DDS-DNA and dPEI-DNA both generate signiﬁcant quantities of
mucosal antigen-speciﬁc IgG and IgA antibody
An important hallmark of mucosal vaccines is their ability to generate
effective local responses and currently most, if not all, vaccine-elicited
protective responses are mediated through humoral immunity. We
assessed the ability of nasal applications of DDS-DNA and dPEI-DNA com-
plexes to generate antigen-speciﬁc antibody responses at a distalmucosal
site. Vaginal lavage samples were assayed for the presence of vaccine
antigen-speciﬁc IgG and IgA (Fig. 4). We found signiﬁcant quantities of
antigen-speciﬁc IgG antibodies in the vaginal lavage samples of animals
that had received either the DDS-DNA or dPEI-DNA primes followed by
CN54gp140 boost vaccination regimens, with mean concentrations of
32.8 ng/ml (**p = 0.005) and 248.2 ng/ml (**p = 0.005) respectively
(Fig. 4a). This was also the case for vaccine-speciﬁc IgA production, with
mean antigen-speciﬁc IgA concentrations of 108.5 ng/ml (*p = 0.0285)
and 311 ng/ml (**p = 0.005) respectively being produced by the DDS-
DNA and dPEI-DNA prime CN54gp140 boost regimens (Fig. 4b). Hence
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more antigen-speciﬁc mucosal antibody than DDS.
3.5. A dPEI-DNA prime-protein boost regimen can protect against
inﬂuenza challenge infection in mice
The generation of vaccine-mediated humoral and cellular immune
responses is important for the protection against viral infections but
a deﬁnitive test for any potential vaccine and delivery vehicle is pro-
tection against a live viral challenge. In the absence of a small animalmodel for HIV-1 infection, we used the dPEI-DNA and DDS-DNA
complexed plasmid DNA (expressing an HA transgene) vaccine as
delivery agents in an X-31 murine-adapted reassortment inﬂuenza
virus infection-challenge model [13]. We ﬁrst cloned the A/Aichi/2/
1968(H3N2) haemagglutinin (HA) gene sequence, codon optimised
for expression in mice, into the pmaxFP™-Red C destination vector
to create a plasmid DNA vaccine. As multiple pulmonary protein vac-
cinations in mice can generate protective immune responses against
inﬂuenza virus challenge, even with concentrations as low as 1 μg/
100 μl dose (data not shown), we altered the vaccination regimen
to incorporate a single protein HA boost. This regimen alteration
would allow us to evaluate the contribution of the mucosal DNA
priming by the two transfection reagents to any protection from infec-
tion with the single protein boost only serving to amplify any cation-
DNA generated immune response. We found that for this DNA encoded
transgene that the dPEI-DNA polyplex but not the DDS-DNA lipoplex
was able to generate signiﬁcant antigen-speciﬁc humoral responses
against the HA protein (**p = 0.0037) (Fig. 5a). The dPEI-DNA also
generated signiﬁcant cellular responses against the HA protein when
splenocytes were used in an IFN-γ ELISpot assay (*p = 0.03) (Fig. 5b).
Nasal antibody lavage revealed the dPEI-DNA treatment regimen to
signiﬁcantly increase antigen-speciﬁc IgG (Fig. 5c) and IgA (Fig. 5d)
compared to DDS-DNA (**p = 0.0087 and *p = 0.026 respectively)
treatment group and negative controls (**p = 0.0043 and **p =
0.0037 respectively). Upon challenge of these cation-DNA primed and
HA-protein boosted animals with a live virus, a signiﬁcant reduction in
infection was observed in dPEI-DNA vaccinated mice (**p = 0.0043)
(Fig. 5f) with a signiﬁcantly reduced morbidity as measured by
weight loss (**p = 0.0022) observed during the challenge (Fig. 5e).
The DDS-DNA priming strategy did not generate signiﬁcant humoral
or cellular responses compared to the negative control group but
did result in signiﬁcantly reduced infection-associated weight loss
(*p = 0.0411) (Fig. 5e). However the infection associated weight
loss for the DDS-DNA treatment group was less than that for the
dPEI-DNA treatment group.
3.6. dPEI-DNA polyplexes can transfect human mucosal epithelium and
traverse epithelial monolayers
To evaluate dPEI as a DNA delivery agent in people, we utilised a
human derived stratiﬁed epithelial tissue model. The tissue contained
a multi-layered, intact overlying epithelium (Fig. 6a) and stroma.
Both, the epithelium and stroma had numerous MHC Class II positive
APCs throughout (Fig. 6b). Incubation of the tissue explants with a
dPEI-DNA polyplex consisting of dPEI and a GFP-encoding plasmid
revealed that transfection occurred within the epithelial layer. Here
both superﬁcial epithelial cells and cells residing deeper in the epi-
thelium can be transfected using a GFP expressing dPEI-DNA com-
plex (Fig. 6c and d). To investigate how the polyplex formulations
interacted with intact epithelium and to explain how they penetrated
tissues after topical application, we utilised transwell systems. HereFig. 6. dPEI polyplexes transfect humanmucosal epithelial cells and can facilitate trans-
fection of stromal cells. Human penile glans tissue, cut into 3 mm × 3 mm explants was
transfected with GFP expressing plasmid complexed to dPEI. Negative control tissue
stained with DAPI and Wheat Germ Agglutinin (WGA) (A), MHC Class II (HLA-DR) ex-
pression (B) and GFP expression (C and D) was examined 48 h post transfection using
a ﬂuorescent microscope. Mucosal epithelium is indicated by the white dotted lines
while GFP expressing cells (green) are indicated by red arrows. Transwell inserts
containing apically cultured conﬂuent monolayers of Caco-2 cells were transfected
with dPEI-GFP polyplexes (E). After 4 h, the media in the basal chamber were removed
and added to CHO cells to evaluate polyplex migration through mucosal epithelium
(F). Negative control Caco-2 cells grown on transwell inserts (G). Transepithelial elec-
trical resistance (TEER) was monitored for 4 h following application of 0–5 μg dPEI-GFP
polyplexes (H). Luciferase expression from dPEI transfected cells is expressed as rela-
tive light units (RLU) for apical Caco-2 (I) and basolateral CHO (J) cell lines.
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cinoma Caco-2 cell line, while the easy to transfect CHO cell line was
added to the basolateral chamber to act as a transfection acceptor.
Using this experimental system, we found that the transepithelial elec-
trical resistance (TEER) changed dramatically after dPEI-DNA polyplex
application to the Caco-2 containing apical transwell insert. This indi-
cated a modulation of cellular tight junction integrity (Fig. 6h). The
polyplexes were able to facilitate the transfection of apical chamber
Caco-2 cells (Fig. 6e) as well as a CHO acceptor cell line at the highest
concentration of polyplex delivered, when media from the basal
transwell chamber were harvested and incubated with the CHO cell
monolayer (Fig. 6f). Interestingly we show that the dynamics of trans-
fection is dependent on the concentration of polyplex. As the concentra-
tion of polyplex increased (0.5 μg–2 μg DNA), the rate of apical Caco-2
transfection increased (Fig. 6i). However, at the highest concentration
(5 μg DNA) tested, the polyplex ability to transfect the Caco-2 epi-
thelium was reduced, while its ability to transfect the basolateral
CHO cells was increased (Fig. 6j).
4. Discussion
Conventional vaccine strategies employing parenteral routes of
administration work through the elicitation of antibody mediated re-
sponses. However, mucosally delivered vaccines offer the potential to
increase vaccine efﬁcacy through activation of not only systemic, but
mucosal immune responses. The potential to establish protective im-
mune responses against infectious agents exploiting mucosal surfaces
at these portals of entry is thus an area of research receiving intense in-
vestigation. Currently there are only a few mucosal vaccines permitted
for human use that target diseases such as rotavirus, inﬂuenza, polio,
typhoid and cholera. However, only the cold adapted LAIV FluMist™
(MedImmune) and Nasovac (Institute of Experimental Medicine) are
administered via the nasal route [14]. With the exception of the oral
cholera vaccine (ORC-Vax®), all the other mucosal vaccines (including
FluMist™) are live attenuated [14]. Despite attenuation, the use of live
vaccines presents safety concerns, and for disease causative agents
like HIV-1 will unlikely be a viable option due to the risk of reversion
to virulence. Hence alternative vaccine delivery technologies, such as
minimal plasmid based DNA vaccines, provide an attractive option to
deliver vaccine antigens safely and easily. Despite early promising at-
tempts to develop DNA vaccines in preclinical models, DNA based vac-
cines have not as yet been translated effectively to humans [15,16].
From a mucosal vaccine perspective, a major roadblock in the utility
of DNA vaccines has been how to deliver them efﬁciently to mucosal
surfaces, mainly because conventional DNA delivery strategies such
as poly-L-lysine and PEI are highly toxic themselves or have suffered
from low mucosal transfection rates [7,8,17]. However, over the past
few years, newer transfection reagents have been generated, with re-
duced toxicity and increased transfection potential [8,10,18]. Here we
trialled two cationic complexing reagents for their abilities to deliver a
plasmid DNA encoding a model HIV CN54gp140 transgene and gener-
ate antigen-speciﬁc immune responses. We then tested the potential
of these delivery agents with a second plasmid DNA construct encoding
an inﬂuenza transgene for protective efﬁcacy in a murine inﬂuenza
infection-challenge model.
We compared DDS against a deacylated form of PEI for their re-
spective abilities to prime immune responses after a topical mucosal
application. DDS is a cationic lipid emulsion containing DOTAP, 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and Squalene,
previously shown to promote high transgene expression in the
nasal passage in a luciferase reporter system [5]. The deacylated PEI
is a 25 kDa PEI with its residual N-acyl moieties removed, providing
it with greater in vitro and in vivo transfection potential [10]. Both
complexing agents displayed reduced toxicity compared to the toxic
N9 positive control in an MTT assay employing a simple columnar
mucosal epithelial cell line Caco-2. Furthermore, DDS and dPEI bothdisplayed reduced toxicity compared to 25 KDa bPEI, a common
transfection reagent, suggesting that both these compounds have an
improved potential for future investigations involving topical muco-
sal application.
DDS and dPEI plasmid DNA complexeswere both able to induce sys-
temic and mucosal humoral immune responses against gp140, as well
as cellular responses in the peripheral blood and splenocyte compart-
ments. Speciﬁc responses to the HIV CN54gp140 model antigen were
generally greater and achieved signiﬁcance more often for dPEI formu-
lations than for DDS formulations. Speciﬁcally dPEI generated highly
signiﬁcant serum IgG, mucosal IgG and IgA antibody levels, as well as
CD4 and CD8 T cell responses capable of producing IFN-γ, IL-2 and
TNF-α in splenocyte cultures. On the other hand, while DDS generated
signiﬁcant serum IgG we observed elevated but not signiﬁcantly
increased IgG and IgA SFU's in splenocyte cultures and only CD4 T
cells which secreted IFN-γ and IL-2 but not TNF-α. Priming with the
DDS-DNA formulations generated CD8 T cells which secreted only
IFN-γ. Themajority of CD8 T cell responseswere against the 1st peptide
pool (Env 1), which contains the ﬁrst 78 overlapping peptides of
CN54gp140. This observation is in line with other ﬁndings which
show limited vaccine-induced CD8+ T cell repertoires being generated
primarily due to suppression by immunodominance mechanisms
[19–22]. Certainly, within the 1st peptide pool, Env structures such as
C1, V1/V2, C2, V3 and partial C3 regions are present, while in the
2nd peptide pool, the remainder of the C3 region, V4, C4, V5 and C5
exists. In the future it would be interesting to precisely map these
immunodominant peptides to regions on CN54gp140. This would
allow for the investigation into the possible ampliﬁcation of alterna-
tive repertoires of functional T cells and if delivered as a component
in a multi-construct formulation, might serve to amplify immune
breadth and add further selective pressure on infecting virions, lead-
ing to more diverse and efﬁcacious vaccine strategies. This is sup-
ported by work investigating the substitution of immunodominant
epitopes in favour of weak, subdominant epitopes in a number of
virus challenge models [19,23,24].
Numerous studies have shown that nasal immunisation can induce
IgA and IgG antibodies as well as effector T cells in the genital tract
[11,25,26]. Moreover, a number of studies have shown that mucosal
vaccination has the capacity to generate long term CD8 T cell responses
[27]. This is of particular interest for vaccines developed to combat sex-
ually transmitted infections as the genital mucosa is known to be a poor
site of immune induction. Within this current study we have demon-
strated that a non-viral DNA strategy can facilitate strong and effective
immune priming that is present in the genital tract due to mucosal im-
mune linkage. Furthermore, it is in agreementwith previous publications
demonstrating that DNA vaccines administered to the respiratory tract
can elicit effective cellular and humoral responses and be protective
against viral infection [1,2,16]. The murine nasal mucosa has a surface
area of 0.3 cm2 and consists of pseudostratiﬁed ciliated single columnar
epithelium and in the lateral turbinates, M cells [28]. This makes the
nasal passages an efﬁcient antigen sampling portal which can be ex-
ploited for vaccine delivery. Herewe show that polyplexes canmodulate
tight junction integrity within a mucosal columnar epithelium cell line.
Furthermore, we show that polyplexes can facilitate the transfection of
superﬁcial epithelium, and at higher concentration, cells residing under-
neath the columnar epithelium. This is supported by our humanmucosal
explant model system, where we demonstrate that plasmid delivery
using dPEI can transfect both superﬁcial epithelium and cells deeper
within the epithelium. This suggests that depending on the concentra-
tion of the delivered polyplexes, a range of cell types can be transfected
when delivered via mucosal routes. It is likely that a combination of
both free PEI in the polyplex formulation, a necessity for efﬁcient gene
transfer, and the intrinsic permeation enhancing properties of PEI may
play a role in subepithelial transfections. In our human explant model
we show that transfection can occur in areas likely to contain residing
APCs such as Langerhans cells. Here no GFP positive cells were seen
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epithelium and underlying stromal cells can be transfected. A recent
study byWegmann et al., 2012 demonstrated that intranasal vaccination
with PEI-gp140 protein formulations resulted in up take by epithelial
and microfold cells of the NALT. Furthermore they show that ﬂuores-
cently labelled gp140 could be found associated with DCs in draining
cervical lymph nodes 24 h post application [29]. Hence suggesting
that both DNA and protein vaccines formulatedwith PEI can enhance
vaccine penetration via the mucosal route. Our results indicate that
dPEI is a superior plasmid DNA transfection reagent than DDS when
administered topically via the pulmonary route andmoreover, can elicit
effective antigen-speciﬁc immune responses that protect mice in an in-
ﬂuenza challenge model at mucosal portals of infection.
In conclusionwehave conducted a head to head study using topically
applied, pulmonary delivered dPEI or DDS complexing agents to enable
efﬁcient plasmid DNA mucosal vaccination and have shown that the
resulting immune response differs quantitatively and qualitatively be-
tween the two complexing agents. Although both were protective in
an inﬂuenza challenge model, dPEI was superior in terms of the magni-
tude of humoral and cellular responses. This has potential implications
for future vaccine regimen design as we have shown that dPEI can be
effectively utilised as a mucosally directed DNA priming strategy.
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